Prosecution Insights
Last updated: November 18, 2026
Application No. 17/883,263

ASSESSING RETINAL PIGMENT EPITHELIAL CELL POPULATIONS

Non-Final OA §112
Filed
Aug 08, 2022
Priority
Dec 30, 2014 — provisional 62/097,753 +4 more
Examiner
NOBLE, MARCIA STEPHENS
Art Unit
1632
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Cell Cure Neurosciences Ltd.
OA Round
6 (Non-Final)
67%
Grant Probability
Favorable
6-7
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 67% — above average
67%
Career Allowance Rate
580 granted / 864 resolved
+7.1% vs TC avg
Strong +40% interview lift
Without
With
+39.6%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
43 currently pending
Career history
915
Total Applications
across all art units

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Withdrawn Rejection The rejection of claim(s) 1, 3-4, and 26-30, under 35 U.S.C. 103 as being unpatentable over Srivastava (Srivastava et al. Journal of Immunological Methods 389:61-68, 2013) in further view of Choudhary (US 2015/0159134 pub date:6/11/2015; effectively filed: 12/11/2013), is withdrawn. Applicant’s argument regarding “95% of said RPE cells of the population” is found persuasive. Further, the combined art does not teach or suggest “qualifying whether…RPE..cell population is suitable for treating a retinal disease or disorder” and does not teach or suggest, “qualifying said population as being a suitable therapeutic for treating the retinal disease or disorder when at least 95% of said RPE cells of the population co-express CRALBP and PMEL17”. Claim Rejections - 35 USC § 112 Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1, 3-4, and 26-30 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Independent claim 1 is indefinite because the claims as amended not longer provide a relationship between the measuring of PEDF and VEGF and qualifying said population as being suitable as a therapeutic. Step (iii) measures PEDF and VEGF and requires the RPE cells of the population to be polarize. Step (iv) qualifies the RPE cell of the population as a suitable therapeutic based upon co-expression of CRALBP and PMEL17 expression but does not the measurements from step (iii). As such, it is not apparent how the measuring step of (iii) is involved in qualifying said population as being a suitable therapeutic. Claims 3-4, and 26-30 depend upon claims and as such also comprise the indefinite issues of claim 1. No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MARCIA STEPHENS NOBLE whose telephone number is (571)272-5545. The examiner can normally be reached M-F 9-5:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Peter Paras can be reached at 571-272-4517. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. MARCIA S. NOBLE Primary Examiner Art Unit 1632 /MARCIA S NOBLE/ Primary Examiner, Art Unit 1632
Read full office action

Prosecution Timeline

Show 7 earlier events
Nov 04, 2025
Request for Continued Examination
Nov 06, 2025
Response after Non-Final Action
Dec 03, 2025
Non-Final Rejection mailed — §112
Mar 03, 2026
Response Filed
May 18, 2026
Final Rejection mailed — §112
Sep 17, 2026
Request for Continued Examination
Sep 21, 2026
Response after Non-Final Action
Sep 30, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12774451
METHODS FOR IMPROVING FUNCTIONALITY IN NK CELL BY GENE INACTIVATION USING SPECIFIC ENDONUCLEASE
8y 11m to grant Granted Oct 27, 2026
Patent 12772964
BLUE TRANSGENIC FLUORESCENT ORNAMENTAL FISH
3y 4m to grant Granted Oct 27, 2026
Patent 12767932
METHOD FOR PREPARING ANIMAL TISSUE-DERIVED BIOMATERIAL, ANIMAL TISSUE-DERIVED BIOMATERIAL PREPARED THEREBY, AND 3D PRINTING METHOD USING SAME
4y 0m to grant Granted Oct 20, 2026
Patent 12746258
HYDROGEL SYSTEMS FOR SKELETAL INTERFACIAL TISSUE REGENERATION APPLIED TO EPIPHYSEAL GROWTH PLATE REPAIR
3y 7m to grant Granted Sep 29, 2026
Patent 12742155
AVIAN ENTEROIDS
4y 8m to grant Granted Sep 22, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

6-7
Expected OA Rounds
67%
Grant Probability
99%
With Interview (+39.6%)
High
PTA Risk
Based on 864 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month